Literature DB >> 8970874

Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents.

N R Puttagunta1, W A Gibby, G T Smith.   

Abstract

RATIONALE AND
OBJECTIVES: The authors compare in vivo transmetallation of three magnetic resonance contrast agents in humans in terms of their kinetic stability.
METHODS: Blood and urine samples were taken before and after the intravenous injection of gadolinium (Gd)-HP-DO3A, Gd-DTPA, or Gd-DTPA-BMA at 0.1 mmol/kg to healthy volunteers. Serum and urine were assayed for zinc, copper, and Gd, using inductively coupled plasma atomic emission spectrometer.
RESULTS: Gadolinium-DTPA-BMA caused the highest increase in zinc excretion among the three agents. Gadolinium-HP-DO3A did not cause a significant increase in zinc excretion. In serum, although Gd-DTPA-BMA exhibited a decrease in zinc concentration, the difference between the drugs was not statistically significant.
CONCLUSIONS: The difference in observed zinc excretion among the chelates studied reflects in vivo transmetallation of the magnetic resonance contrast media and correlates with the respective kinetic inertia for transmetallation, rather than thermodynamic stability constants. Gadolinium-HP-DO3A was found to be the most kinetically inert among the three drugs tested.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8970874     DOI: 10.1097/00004424-199612000-00001

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  18 in total

1.  Stability and biodistribution of a biodegradable macromolecular MRI contrast agent Gd-DTPA cystamine copolymers (GDCC) in rats.

Authors:  Xueming Wu; Yuda Zong; Zhen Ye; Zheng-Rong Lu
Journal:  Pharm Res       Date:  2010-07       Impact factor: 4.200

Review 2.  A Review of the Current Evidence on Gadolinium Deposition in the Brain.

Authors:  Richard Pullicino; Mark Radon; Shubhabrata Biswas; Maneesh Bhojak; Kumar Das
Journal:  Clin Neuroradiol       Date:  2018-03-09       Impact factor: 3.649

Review 3.  Gadolinium-Based Contrast Agent-Related Toxicities.

Authors:  Luca Pasquini; Antonio Napolitano; Emiliano Visconti; Daniela Longo; Andrea Romano; Paolo Tomà; Maria Camilla Rossi Espagnet
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

4.  The fate of Gd and chelate following intravenous injection of gadodiamide in rats.

Authors:  Grete Mørk Kindberg; Steinar Uran; Grete Friisk; Ivar Martinsen; Tore Skotland
Journal:  Eur Radiol       Date:  2010-02-16       Impact factor: 5.315

Review 5.  Primer on gadolinium chemistry.

Authors:  A Dean Sherry; Peter Caravan; Robert E Lenkinski
Journal:  J Magn Reson Imaging       Date:  2009-12       Impact factor: 4.813

6.  Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents.

Authors:  Peter J Wermuth; Francesco Del Galdo; Sergio A Jiménez
Journal:  Arthritis Rheum       Date:  2009-05

7.  Synthesis and evaluation of a polydisulfide with Gd-DOTA monoamide side chains as a biodegradable macromolecular contrast agent for MR blood pool imaging.

Authors:  Zhen Ye; Xueming Wu; Mingqian Tan; Jack Jesberger; Mark Grisworld; Zheng-Rong Lu
Journal:  Contrast Media Mol Imaging       Date:  2013 May-Jun       Impact factor: 3.161

Review 8.  Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis.

Authors:  Hale Ersoy; Frank J Rybicki
Journal:  J Magn Reson Imaging       Date:  2007-11       Impact factor: 4.813

Review 9.  Pathophysiology of gadolinium-associated systemic fibrosis.

Authors:  Brent Wagner; Viktor Drel; Yves Gorin
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-04

10.  Safety of contrast-enhanced MR angiography employing gadobutrol 1.0 M as contrast material.

Authors:  Jörn O Balzer; Christian Loewe; Kirsten Davis; Mathias Goyen; Tim Leiner; James F M Meaney; Christiane Pöckler-Schöniger; Gernot Schulte-Altedorneburg; Bernd Tombach; Rolf Vosshenrich; Robin Wegener
Journal:  Eur Radiol       Date:  2002-12-03       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.